WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016090250) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING GRAFT VERSUS HOST DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/090250    International Application No.:    PCT/US2015/064001
Publication Date: 09.06.2016 International Filing Date: 04.12.2015
IPC:
A61K 35/12 (2015.01)
Applicants: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 100 Europa Drive, Suite 430 Chapel Hill, NC 27517 (US).
REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Mcnamara Alumni Center 200 Oak St. Se, Suite 600 Minneapolis, MN 55455 (US)
Inventors: SERODY, Jonathan; (US).
COGHILL, James; (US).
BRUCE, Danny; (US).
BLAZAR, Bruce; (US).
STEFANSKI, Heather; (US).
VINCENT, Benjamin; (US)
Agent: TAYLOR, Arles, A.; (US)
Priority Data:
62/087,340 04.12.2014 US
Title (EN) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING GRAFT VERSUS HOST DISEASE
(FR) COMPOSITIONS ET MÉTHODES POUR PRÉVENIR ET TRAITER LA MALADIE DU GREFFON CONTRE L'HÔTE
Abstract: front page image
(EN)ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
(FR)Des cellules ILC2 jouent un rôle dans la pathogénèse de la maladie du greffon contre l'hôte (GvHD) et du syndrome de la pneumonie idiopathique (IPS), les deux états étant associés à la transplantation de cellules souches allogéniques. La perfusion de cellules ILC2 activées par IL -33 chez des patients atteints de GvHD ou IPS, ou avant l'apparition de GvHD ou IPS chez des patients susceptibles de les contracter, améliore sensiblement la maladie et la survie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)